Skip to main content

Table 1 Participant characteristics

From: Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on 18F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine

 

Total (n = 573)

AZ group (n = 263)

M group (n = 310)

p-valuea

Age (years)

64 ± 12

62 ± 15

67 ± 9

 < 0.0001

Sex, female

279 (49%)

137 (52%)

142 (46%)

0.13

Vaccination dose

   

0.002

 First dose

478 (83%)

 

271 (87%)

 

 Second dose

98 (17%)

204 (78%)

39 (13%)

 

Injected site

   

0.78

 Left arm

492 (86%)

227 (86%)

265 (85%)

 

 Right arm

81 (14%)

36 (14%)

45 (15%)

 

Time interval between PET and vaccination (days)

51 ± 29

50 ± 30

53 ± 29

0.41

  1. All data were expressed in mean ± SD
  2. AZ, Oxford-AstraZeneca; M, Moderna; PET, positron emission tomography
  3. a Comparison between the AZ and M groups